Introduction {#s001}
============

H[ypoglycemi]{.smallcaps}[a is a serious acute metabolic complication]{.smallcaps} of type 1 diabetes (T1D).^[@B1]^ Recurrent hypoglycemia may lead to impaired awareness of hypoglycemia (inability to recognize symptoms of hypoglycemia) and severe hypoglycemia (requiring third-party assistance to treat), both of which are associated with increased morbidity and mortality.^[@B2]^ Hypoglycemia, especially severe hypoglycemia, adds a significant burden to the health cost worldwide.^[@B6]^

Capillary finger-prick blood glucose testing remains the mainstay of self-monitoring of blood glucose (SMBG) among people with T1D, but uptake of intermittent flash glucose monitoring (flash) and real-time continuous glucose monitoring (RT-CGM) devices is increasing.

RT-CGM has been shown to improve HbA1c and reduce hypoglycemia in people with T1D established on pump therapy and multiple daily injections (MDI) of insulin with suboptimal glycemic control.^[@B7]^ RT-CGM also increases time spent in normoglycemia and reduces severe hypoglycemia in T1D participants with impaired awareness of hypoglycemia, compared with SMBG,^[@B12],[@B13]^ and reduces diabetes-related distress.^[@B14]^ The largest randomized controlled trial (RCT) evaluating flash versus standard care is the IMPACT study that included T1D participants with HbA1c close to target and intact hypoglycemia awareness on MDI of insulin or pump therapy. Flash use was associated with a 38% reduction in time spent in hypoglycemia (\<3.9 mmol/L \[70 mg/dL\]) and HbA1c remained unchanged after 6 months.^[@B15]^

Both RT-CGM and flash glucose monitoring devices measure interstitial fluid glucose, but only RT-CGM has alarms to alert users to the potential risk of impending hypo- or hyperglycemia. With flash, a real-time glucose value and 8 h of retrospective data with a trend line can be viewed after physically scanning the sensor. Of the current commercially available interstitial glucose monitoring devices, only the Freestyle Libre Flash Glucose Monitoring System and Dexcom G5 and G6 RT-CGM are licensed to be used nonadjunctively (not requiring confirmation with capillary blood glucose) for insulin treatment decisions. In the United Kingdom, NHS England has endorsed guidance for flash, written by the Regional Medicines Optimisation Committee (RMOC),^[@B16]^ that supports the use of flash in people with T1D who undertake intensive monitoring (\>8 times) daily; those who fit the current NICE criteria for insulin pump therapy (HbA1c \>8.5%) or disabling hypoglycemia (NICE TA151); those who have recently developed impaired awareness of hypoglycemia; if frequent (\>2/year) admission with diabetic ketoacidosis or hypoglycemia; and those who require third-party assistance to carry out recommended monitoring. These indications overlap with the NICE guidelines supporting the use of CGM in adults with T1D, which are as follows: \>1 episode of severe hypoglycemia/year; complete loss of awareness of hypoglycemia; frequent (\>2 episodes/week) asymptomatic hypoglycemia that is causing problems with daily activities; extreme fear of hypoglycemia; and HbA1c ≥9% despite testing ≥10 times/day.^[@B17]^

The I HART CGM study was the first head-to-head RCT comparing flash (Freestyle Libre) to RT-CGM (Dexcom G5) in people with T1D at high risk of hypoglycemia and showed a significantly greater reduction in percentage of time spent in hypoglycemia in the RT-CGM group compared with the flash group over 8 weeks; however, no significant differences between the groups in Gold Score or HbA~1c~ from baseline to endpoint were observed.^[@B18]^ All participants were given the opportunity to participate in an 8-week extension phase evaluating the impact of switching from flash to RT-CGM and continuing with RT-CGM in those already on RT-CGM to establish its impact on extended use. In this article, we present the glycemic outcomes from the I HART CGM study extension phase, and throughout the article, the study groups are referred to as the flash group and RT-CGM group according to randomization at baseline.

Methods {#s002}
=======

Participants and study design {#s003}
-----------------------------

The I HART CGM study is a randomized, nonmasked parallel group study with an extension phase at a single diabetes specialist site in the United Kingdom. Ethics approval was obtained from the London - Hampstead Research Ethics Committee (Reference no.: 15/LO/1679). The inclusion criteria were as follows: age ≥18 years, T1D (confirmed by a fasting c-peptide \<200 pmol/L and clinical features) ≥3 years, on an intensified MDI regimen for \>6 months, and a severe hypoglycemic event in the last 12 months requiring third-party assistance or a Gold Score ≥4. All participants had undergone T1D education, either as a group or in a one to one session with a specialist educator. Participants were excluded if they had used CGM or flash within the last six months (except short periods of diagnostic blinded use under clinic supervision), used regular paracetamol, were pregnant or planning pregnancy, breastfeeding, enrolled in other clinical trials, had active malignancy or were under investigation for malignancy, had severe visual impairment, or reduced manual dexterity. Written informed consent was obtained from all participants.

Procedures {#s004}
----------

Screening included a medical history, a physical examination, electrocardiogram, fasting venous blood tests (HbA1c, plasma glucose, urea and electrolytes, cortisol, and serum C-peptide), urine for urine microalbuminuria and pregnancy test in women of childbearing age, and validated questionnaires (Gold Score, Hypoglycemia Fear Score II \[HFS-II\], and Problem Areas in Diabetes \[PAID\] questionnaires). A brief T1D education refresher was provided. Participants then commenced a 2-week run-in phase using the Dexcom G4 sensor with a blinded receiver running the advanced "505" algorithm that stores glucose data but does not make them available to the participant. The sensor was calibrated to capillary blood glucose values twice daily as per the manufacturer\'s guidance. Participants were randomly assigned to CGM (Dexcom G5) or flash glucose monitoring (Abbott Freestyle Libre) in a 1:1 ratio by an online randomization tool ([www.sealedenvelope.com](www.sealedenvelope.com)). Randomization was stratified by HbA1c (HbA1c \<58 or ≥58 mmol/mol). Participants then received standardized CGM education for the RT-CGM or flash devices and both devices were used in accordance with product licenses. Participants were instructed to test their capillary blood glucose if they experienced symptoms of hypo- or hyperglycemia, in case of temporary sensor signal loss or sensor failure. The initial intervention period was 8 weeks and participants were given an option at the end of 8 weeks to continue with RT-CGM (Dexcom G5) for another 8 weeks, irrespective of which device they were randomized to for the initial 8 weeks of the study. The complete study design is illustrated in [Figure 1](#f1){ref-type="fig"} and this article focuses on the extension phase of the study (weeks 9--16). The details of study visits for the first 8-week intervention period have been published.^[@B18]^ Those participants who decided to participate in the 8-week extension phase using RT-CGM (Dexcom G5), using either the G5 receiver or the G5 app on their smartphone, entered this phase immediately after completing the first 8-week intervention and those initially randomized to flash were given standardized RT-CGM education. Participants then attended the clinical research facility after 8 weeks (at 16 weeks from initial study start) for a venous blood test for HbA1c and completed the Gold Score, HFS-II, and PAID questionnaires. CGM data were downloaded from their G5 receiver to Diasend (for app users, data upload was automatic). The participants were provided with a contact number for technical support, but insulin titration decisions were made by the participant throughout the study.

![Study design and participant recruitment.](fig-1){#f1}

Statistical analysis {#s005}
--------------------

Outcomes for the I HART CGM extension phase were percentage time spent in hypoglycemia (\<2.8, \<3.0, and 3.9 mmol/L), percentage time in euglycemia (3.9--7.8 mmol/L), percentage time spent in target (3.9--10 mmol/L), percentage time spent in hyperglycemia \>7.8, \>10, and \>15 mmol/L, severe hypoglycemia (requiring third-party assistance to treat), hypoglycemia risk, HbA1c, and Gold Score. Data were analyzed using Stata v14 (StataCorp, TX). The majority of variables were non-normally distributed and summary statistics therefore presented as median (IQR). For the extension phase, the change from the 8-week endpoint outcomes of the randomized phase to the 16-week endpoint of the extension phase was calculated for each group and the difference in change between groups is analyzed.

All outcomes from the extension phase were considered to be secondary outcomes and comparisons were considered hypothesis generating and informative. The Wilcoxon matched-pair signed rank test was used for analysis of changes within each group and the Wilcoxon rank sum test used for comparing changes between groups. Analysis was by intention to treat. The 8-week endpoint glucose data were taken from the last 28 days of the initial treatment period and 16-week endpoint outcomes calculated from the last 28 days of the final treatment period. All outcomes are based on comparisons of the 8-week endpoint and 16-week endpoint unless mentioned otherwise. The study is registered at [ClinicalTrials.gov,](ClinicalTrials.gov,) number NCT03028220.

Results {#s006}
=======

Thirty-six adults with T1D (all participants had a c-peptide of less than 200 pmol/L) on intensified multiple daily insulin injections and with impaired awareness of hypoglycemia or a recent episode of severe hypoglycemia were included. Of the initial 40 participants included in the I HART CGM study, four participants in the RT-CGM group did not complete the second 8-week treatment period with RT-CGM (one participant decided not to partake in the second treatment period (no reason given), one participant lost the transmitter during the treatment period and did not inform the study team, one participant could not commit to the study due to work, and one participant did not comply with the study protocol and was excluded from the study). An overview of the recruitment is given in [Figure 1](#f1){ref-type="fig"}. For outcomes derived from CGM data, *n* = 15 were analyzed in the RT-CGM group due to loss of the initial 8-week intervention CGM data for one participant (uploading error).

There was a significant reduction in percentage time in clinically relevant hypoglycemia (\<3.0 mmol/L) in the flash group after switching to RT-CGM (5.0 \[3.7--8.6\] vs. 0.8 \[0.4--1.9\], *P* \< 0.001) and no change was observed in the RT-CGM group that continued with RT-CGM (1.3 \[0.4--2.8\] vs. 1.3 \[0.8--2.5\], *P* = 0.82). A significant difference in reduction between the groups was observed (*P* \< 0.001). The median difference, from the 8-week endpoint to the 16-week endpoint, between groups was significant for all predefined thresholds of hypoglycemia when switching from flash to RT-CGM.

There was no significant change in HbA1c within or between groups. Results are summarized in [Table 1](#T1){ref-type="table"}. [Figure 2](#f2){ref-type="fig"} shows the percentage time in clinically important hypoglycemia (\<3.0 mmol/L) and percentage time in target (3.9--10 mmol/L) at baseline, at the 8-week endpoint and at the 16-week endpoint. In summary, the percentage time in hypoglycemia is significantly reduced from baseline to 8 weeks with RT-CGM and the improvement is maintained when continued for another 8 weeks, whereas in the flash group, the percentage time in hypoglycemia remains the same between baseline and the 8-week endpoint; however, when switched to RT-CGM, there is a significant reduction in hypoglycemia at the 16-week endpoint. There were no episodes of severe hypoglycemia requiring third-party assistance in either group throughout the study intervention periods.

![Percentage time in hypoglycemia (\<3.0 mmol/L) **(a)** and in target range (3.9--10 mmol/L) **(b)** at baseline (weeks −2 to 0), at 8-week endpoint (weeks 4--8), and at 16-week endpoint. The bar charts represent median (IQR) and the range (minimum to maximum).](fig-2){#f2}

###### 

[Change in Glucose Outcomes and Questionnaire Outcomes (Gold, HSF-II \[Including HSF-II Behavior and Worry Subscores\] and PAID Scores) from 8 Weeks to Endpoint at 16 Weeks with RT-CGM]{.smallcaps}

  *% Time in defined glucose range*   *RT-CGM group (*n* = 16)*   *Flash glucose monitoring group (*n* = 20)*   *Median change from 8 weeks to endpoint*                                                                                                         
  ----------------------------------- --------------------------- --------------------------------------------- ------------------------------------------ --------------------- --------------------- ------------- --------------------- --------------------- -------------
  \<2.8 mmol/L                        0.8 (0.2 to 1.7)            0.9 (0.3 to 1.5)                              0.82                                       3.8 (3.0 to 6.4)      0.5 (0.2 to 1.4)      **\<0.001**   0.0 (−0.9 to 0.3)     −3.1 (−4.6 to −2.4)   **\<0.001**
  \<3.0 mmol/L                        1.3 (0.4 to 2.8)            1.3 (0.8 to 2.5)                              0.82                                       5.0 (3.7 to 8.6)      0.8 (0.4 to 1.9)      **\<0.001**   0.02 (−1.2 to 0.5)    −4.0 (−4.8 to −2.9)   **\<0.001**
  \<3.3 mmol/L                        2.3 (0.9 to 4.4)            2.1 (1.4 to 4.4)                              0.73                                       6.8 (4.8 to 11.7)     1.5 (0.7 to 2.8)      **\<0.001**   0.4 (−1.7 to 0.9)     −4.8 (−6.2 to −3.2)   **\<0.001**
  \<3.5 mmol/L                        3.1 (1.5 to 5.9)            3.3 (2.2 to 6.7)                              0.77                                       8.2 (6.0 to 13.2)     2.1 (1.2 to 4.0)      **\<0.001**   0.4 (−2.3 to 1.7)     −5.3 (−7.6 to −3.3)   **\<0.001**
  \<3.9 mmol/L                        6.2 (3.1 to 8.7)            5.4 (3.9 to 9.7)                              0.86                                       11.0 (8.2 to 17.0)    3.9 (2.4 to 6.7)      **\<0.001**   0.4 (−0.2 to 2.1)     −6.6 (−9.4 to −3.7)   **\<0.001**
  \>7.8 mmol/L                        49.0 (43.9 to 56.8)         45.6 (40.4 to 63.5)                           0.99                                       47.1 (37.4 to 53.5)   50.2 (44.7 to 57.8)   **0.007**     −0.3 (−5.5 to 6.6)    3.7 (−0.9 to 15.2)    **0.02**
  \>10 mmol/L                         26.7 (17.5 to 36.1)         28.8 (15.8 to 46.3)                           0.82                                       28.0 (18.0 to 32.1)   27.8 (23.0 to 34.3)   **0.02**      −1.0 (−5.4 to 8.5)    4.5 (−1.5 to 9.1)     0.18
  \>15 mmol/L                         4.2 (1.2 to 8.8)            4.8 (1.4 to 9.1)                              0.71                                       2.6 (1.2 to 5.1)      2.7 (2.3 to 5.0)      0.09          0.1 (−0.9 to 2.1)     0.6 (−0.3 to 2.8)     0.36
  3.9 to 7.8 mmol/L                   43.7 (38.1 to 47.8)         43.1 (32.1 to 54.0)                           0.69                                       40.4 (34.7 to 45.3)   42.9 (34.9 to 49.8)   0.68          1.0 (−2.6 to 3.2)     2.2 (−5.2 to 4.7)     0.81
  3.9 to 10 mmol/L                    65.9 (54.1 to 74.8)         64.9 (49.2 to 73.9)                           0.64                                       60.0 (54.5 to 67.8)   67.4 (56.3 to 72.4)   **0.02**      −1.0 (−4.4 to 4.1)    3.5 (−0.4 to 7.2)     **0.04**
  Other outcomes                                                                                                                                                                                                                                                 
   Low blood glucose index            4.8 (2.8 to 6.3)            4.6 (3.8 to 5.9)                              0.69                                       9.1 (7.2 to 10.7)     4.1 (3.0 to 4.9)      **\<0.001**   0.2 (−1.4 to 1.2)     −4.8 (−6.2 to −2.3)   **\<0.001**
   Gold score                         5.0 (3.0 to 5.0)            4.5 (3.0 to 6.0)                              0.82                                       5.0 (3.5 to 6.0)      4.5 (3.0 to 5.5)      **0.04**      0 (−1 to 0.5)         0 (−1 to 0)           0.46
   HbA1c mmol/mol                     54.0 (46.0 to 62.0)         51.5 (47.0 to 58.0)                           0.87                                       51.0 (48.5 to 59)     52.0 (49.5 to 60.5)   0.07          0.5 (−5.5 to 4.5)     2.0 (0.0 to 3.0)      0.49
   HSF-II total score                 54.0 (28.0 to 78.0)         47.0 (29.5 to 73.2)                           0.07                                       42.0 (27.7 to 66.7)   38.0 (27.5 to 50.5)   0.15          −4.5 (−10.7 to 1.7)   −1.5 (−12.0 to 4.5)   0.94
   HSF-II behavior                    20.0 (11.0 to 28.5)         18.5 (10.2 to 24.7)                           0.46                                       15.0 (11.2 to 27.7)   15.5 (11.2 to 22.7)   0.70          0.0 (−4.7 to 2.5)     −1.8 (−5.0 to 1.0)    0.41
   HSF-II worry                       32.0 (16.7 to 49.7)         29.5 (18.2 to 40.5)                           0.18                                       31.0 (15.2 to 47.0)   21.5 (14.0 to 36.5)   **0.02**      −2.0 (−10.0 to 2.0)   −3.0 (−10.0 to 0.7)   0.51
   PAID score                         36.2 (10.0 to 52.5)         32.5 (12.5 to 38.7)                           0.23                                       27.5 (15.6 to 55.0)   21.2 (17.8 to 38.4)   0.11          −1.2 (−8.7 to 2.5)    −1.2 (−7.1 to 0.9)    0.82

Results are expressed as median (IQR). *P* values of \<0.05 are significant and highlighted in bold. Outcomes based on CGM data are derived from the last 28 days in each treatment period.

HFS-II, Hypoglycaemia Fear Survey; PAID, Problem Areas in Diabetes; RT-CGM, real-time continuous glucose monitoring.

The percentage time in target improves from baseline to the initial 8-week endpoint with both flash and RT-CGM, however, when the flash group is switched to RT-CGM there is further improvement in time in target at the 16-week endpoint, whereas in the RT-CGM the improvement is sustained, but no further significant improvement observed.

A significant improvement in HFS-II Worry subscore was seen when switching from flash to RT-CGM, whereas no further improvement was seen with continued use in the RT-CGM group. No significant difference in the reduction between groups was observed for HFS-II (including behavior and worry subscores) and PAID scores ([Table 1](#T1){ref-type="table"}).

Discussion {#s007}
==========

Our pilot data suggest that switching from flash to RT-CGM has a significant beneficial impact on hypoglycemia outcomes and that continued use of RT-CGM maintains hypoglycemia risk/benefit in this high-risk population, across all predefined hypoglycemia thresholds. In addition, we have previously shown that percentage time in target improved with both flash and RT-CGM and here we demonstrate that switching from flash to RT-CGM achieves further benefit, whereas continuing with RT-CGM maintains benefit achieved over the first 8 weeks. Hypoglycemia fear resulting from worry improved in those who switched from flash to RT-CGM, however, the overall hypoglycemia fear reduction between groups was nonsignificant. The median Gold Score remained above 4 in both groups at the 16-week endpoint, suggesting that no clinically relevant improvement in hypoglycemia awareness was achieved by switching from flash to RT-CGM or continuing with RT-CGM for an extended time period.

This extension phase of the I HART CGM study is limited by small numbers and a short follow-up period. The glucose data at the 8-week endpoint in the flash and RT-CGM groups were derived from the Abbott Freestyle Libre device and from the Dexcom G5 RT-CGM device, respectively, but the final glucose data at the 16-week endpoint were derived from RT-CGM in both groups. This poses another limitation as previously highlighted^[@B18]^ when comparing outcomes based on two different technologies, where accuracy may not be equivalent and henceforth glucose outcomes may not be directly comparable. This applies when evaluating the difference from baseline to 8-week endpoint and from the 8-week to 16-week endpoint within the flash group. Both devices were used in accordance with the manufacturer\'s guidance. It has been reported that flash overestimates hypoglycemia,^[@B19]^ which may have contributed to the hypoglycemia results seen in our study, but not the time in range or hypoglycemia fear outcomes. Other data suggest that accuracy of flash and RT-CGM is comparable across a wide glucose range, including below hypoglycemia thresholds.^[@B20],[@B21]^ We recognize the importance of a standard reference methodology when comparing different interstitial glucose monitoring technologies in clinical trials.

Our data support the NICE guidance^[@B17]^ that RT-CGM with alarms and alerts should be first line in people with T1D at high risk of hypoglycemia, but contradict the RMOC criteria for flash, which include people with T1D who have recently developed impaired awareness of hypoglycemia. There is an overlap between the two guidance documents, which may cause challenges in clinical practice. Although this is a pilot study with limitations, the data presented here continue to support the view that hypoglycemia risk, including frequency, severity, and awareness, must be assessed before offering diabetes technology interventions to people with T1D and that RT-CGM remains the appropriate first-line glucose monitoring option in hypoglycemia-prone individuals. The data presented here additionally suggest that there is a role for switching to RT-CGM in those already established on flash in this high-risk population and that the benefits of RT-CGM are sustained to 16 weeks.
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[^1]: Some of the results presented in this article was presented as part of an oral presentation at ATTD, Vienna, February 2018.
